5 December 2016: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce positive data from the Company’s Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for stroke disability.